 SAN DIEGO, Feb. 03, 2022 GLOBE NEWSWIRE -- Erasca, Inc. Nasdaq: ERAS, a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RASMAPK pathway-driven cancers, today announced its participation in the Guggenheim Healthcare Talks 2022 Oncology Day. Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer, will represent Erasca in a virtual fireside chat beginning at 2:30 PM Eastern Time on Thursday, February 10, 2022. The company will also participate in one-on-one investor meetings. 